The differential gene expression of the lung cancer cell line HCC827 before and after resistance to osimertinib
Osimertinib, as a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved as a first-line therapy in advanced non–small-cell lung cancer (NSCLC) patients with EGFR-activating or T790M resistance mutations. However, the efficacy of osimertinib is limited due to acquired resistance. In order to search for the mechanism of resistance to osimertinib, we screened on significantly upregulated genes encoding protein kinases in osimertinib-resistant NSCLC cells via RNA-sequence.In summary, our data elucidate the alterations in gene expression within lung cancer cells before and after resistance to osimertinib, aiding in the analysis and identification of key molecules influencing osimertinib resistance. Overall design: To establish resistant cell lines to osimertinib, the parent cells (HCC827) were exposed to gradually increasing concentrations of osimertinib, including 10nM, 50nM, 100nM, 500nM, 1µM, and 5µM. Each concentration gradient was cultured for 1 month. Ultimately, the cells that could grow normally in a culture environment with a concentration of 5µM of osimertinib were defined as osimertinib-resistant cell line (HCC827OR)